The convergence of WWOX deficiency, GLUT1 overexpression, and markers of T-cell exhaustion highlights a critical vulnerability in HCC, suggesting that therapeutic strategies targeting glycolytic-immune crosstalk may hold significant promise. The gene discussed is SLC2A1; the disease is hepatocellular carcinoma.